AOD-9604 vs Retatrutide

AOD-9604 and Retatrutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

AOD-9604 is a modified peptide derived from the human growth hormone (hGH), specifically comprising amino acids 177-191 along with an N-terminal tyrosine. Developed at Monash University, Australia, AOD-9604 retains the lipolytic properties associated with hGH while eliminating its growth-promoting and diabetogenic effects. This modification allows for targeted fat loss without the accompanying risks of abnormal growth or changes in blood glucose levels. In the early 2000s, AOD-9604 was evaluated in six randomized, double-blind, placebo-controlled clinical trials involving obese participants, where it demonstrated a modest average fat loss of approximately 5% body weight. Notably, the side effect profile was comparable to that of the placebo group. Although the FDA granted AOD-9604 GRAS status for food use in 2014, clinical development for obesity indications was halted, limiting further exploration of its therapeutic potential. Key claims regarding AOD-9604 include its ability to promote fat loss without impacting IGF-1 levels and its potential role in cartilage repair.

Retatrutide is a pioneering investigational peptide that acts as a triple hormone receptor agonist, targeting GIP, GLP-1, and glucagon receptors. This innovative mechanism positions Retatrutide as a multifaceted agent in the management of obesity and metabolic disorders. In a Phase 2 clinical trial led by Jastreboff et al. (2023), involving 338 participants, a 12 mg dose of Retatrutide resulted in a remarkable mean body weight reduction of 24.2% over 48 weeks, with all participants achieving at least a 5% weight loss. Currently, multiple Phase 3 TRIUMPH trials are underway, with TRIUMPH-4 expected to report findings by December 2025, indicating an average weight loss of up to 71.2 lbs, alongside improvements in osteoarthritis-related pain. Anticipated FDA approval is projected for 2027-2028. The compelling evidence from these trials underscores Retatrutide's potential in not only facilitating weight loss but also enhancing glycemic control in individuals with type 2 diabetes, marking it as a significant advancement in peptide research.

While AOD-9604 and Retatrutide are both studied in the context of weight management, they target distinct aspects of metabolic health. AOD-9604 is primarily focused on promoting fat loss, leveraging its unique mechanism to help reduce body fat without the adverse effects associated with traditional growth hormone therapies. In contrast, Retatrutide serves a broader role in weight management and metabolic health by acting on multiple hormonal pathways, thereby addressing not only obesity but also related conditions such as type 2 diabetes and osteoarthritis. The divergence in their mechanisms and applications reflects the evolving landscape of peptide research, highlighting the need for tailored approaches depending on specific research goals.

The safety profiles of AOD-9604 and Retatrutide reveal important distinctions that researchers must consider. AOD-9604 has demonstrated a side effect profile that is virtually indistinguishable from placebo in clinical trials, with only mild headaches or flushing reported in a small percentage of participants. Importantly, AOD-9604 does not elevate IGF-1 levels, mitigating risks such as abnormal bone growth or organ enlargement. Conversely, Retatrutide is associated with dose-related gastrointestinal side effects, including nausea, vomiting, diarrhea, and constipation, which were reported in 13-63% of participants across various dose groups. These gastrointestinal events are generally mild to moderate and may be partially alleviated by initiating treatment at a lower dose (2 mg vs. 4 mg). Additionally, dose-dependent increases in heart rate were observed, peaking at 24 weeks before declining. Understanding these safety considerations is essential for researchers when evaluating the suitability of each peptide for their studies.